HIV InfectionsDepVIHNCT07303114
Missed Opportunities for HIV Screening in General Practice
An observational study of HIV Infections, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
The number of new HIV diagnoses in France in 2022 is estimated to be between 4,200 and 5,700. Of these diagnoses, 43% of infections were detected at a late stage. The objective of this study is to identify missed opportunities for HIV testing in general practice and to understand the barriers to testing. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HIV Infections
- How many people
- 50 participants
- Where
- 1 siteFrance
- Study dates
- 14 Apr 2025to Jul 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult subject (≥18 years) diagnosed with HIV infection between January 1, 2021, and July 30, 2024
Who may be able to join
- Adult subject (≥18 years)
- diagnosed with HIV infection between January 1, 2021, and July 30, 2024
Who cannot join
- -Subject who arrived in France in the year preceding or during the period between January 1, 2024, and July 30, 2024.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, 67091
Baptiste Hoellinger, MD, 33 3 69 55 05 45, baptiste.hoellinger@chru-strasbourg.fr
Baptiste Hoellinger, MD
About this study
Official title: Missed Opportunities for HIV Screening in General Practice - A Retrospective Study
The number of new HIV diagnoses in France in 2022 is estimated to be between 4,200 and 5,700. Of these diagnoses, 43% of infections were detected at a late stage. The objective of this study is to identify missed opportunities for HIV testing in general practice and to understand the barriers to testing.
- Conditions
- HIV Infections
- Keywords
- HIV infections, HIV Testing
- Medical subject headings
- HIV Infections
What is being measured
The primary outcome is the main question the study is designed to answer.
Presence or absence of clinical signs suggestive of HIV infection
This is a retrospective analysis of data on the presence or absence of clinical signs suggestive of HIV infection during the year preceding diagnosis
Measured: 1 year preceding HIV diagnosis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2025
- Study start14 Apr 2025
- Primary completionJul 2026 (estimated)
- Study completionJul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07303114
- Sponsor's protocol ID
- 9478
- Acronym
- DepVIH
- Status last verified
- Dec 2025
- First submitted
- 11 Dec 2025
- Last updated
- 5 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Missed Opportunities for HIV Screening in General Practice - A Retrospective Study
- ClinicalTrials.gov ID
- NCT07303114
- Acronym / sponsor ID
- DepVIH / 9478
- Conditions
- HIV Infections
- Keywords
- HIV infections, HIV Testing
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 14 Apr 2025 (actual)
- Primary completion
- Jul 2026 (estimated)
- Study completion
- Jul 2026 (estimated)
- First posted
- 24 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The number of new HIV diagnoses in France in 2022 is estimated to be between 4,200 and 5,700. Of these diagnoses, 43% of infections were detected at a late stage. The objective of this study is to identify missed opportunities for HIV testing in general practice and to understand the barriers to testing.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult subject (≥18 years) diagnosed with HIV infection between January 1, 2021, and July 30, 2024
Key inclusion criteria (2 listed)
- Adult subject (≥18 years)
- diagnosed with HIV infection between January 1, 2021, and July 30, 2024
Key exclusion criteria (1 listed)
- -Subject who arrived in France in the year preceding or during the period between January 1, 2024, and July 30, 2024.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Presence or absence of clinical signs suggestive of HIV infection
Time frame: 1 year preceding HIV diagnosis
This is a retrospective analysis of data on the presence or absence of clinical signs suggestive of HIV infection during the year preceding diagnosis
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2026.
Related trials for HIV Infections
Not yet recruiting
Evaluating the Healthy Families PrEP Program for Women at Risk for HIV
HIV, Pregnancy
RecruitingObservational study
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
HIV
Not yet recruiting
Supporting Health and Empowerment Through Contingency Management and Affect Regulation
HIV Risk
RecruitingPhase 1
HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
Plasmablastic Lymphoma, HIV
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of HIV Infections, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact baptiste Hoellinger, MD (33 3 69 55 05 45, baptiste.hoellinger@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Presence or absence of clinical signs suggestive of HIV infection (time frame: 1 year preceding HIV diagnosis). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2026.